Abstract：
UNASSIGNED: This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF).
UNASSIGNED: We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily.
UNASSIGNED: Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months.
UNASSIGNED: JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.
UNASSIGNED: We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily.
UNASSIGNED: Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months.
UNASSIGNED: JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.
摘要：
■本案例研究旨在报告Janus激酶（JAK）抑制剂治疗全身性嗜酸性脓疱性毛囊炎（EPF）的疗效和安全性。
我们介绍了一例16岁的中国患者，他患有EPF两年，对局部和全身糖皮质激素均无反应。患者随后以每天5mg的剂量口服托法替尼治疗。
■在使用托法替尼治疗后观察到患者的爆发和瘙痒的显著缓解。然而,剂量减少后复发。随后转换为高选择性JAK1抑制剂upadacitinib导致完全恢复，患者在六个月后达到无症状状态。
JAK抑制剂有望成为对传统疗法无反应的EPF患者的潜在治疗选择。
我们介绍了一例16岁的中国患者，他患有EPF两年，对局部和全身糖皮质激素均无反应。患者随后以每天5mg的剂量口服托法替尼治疗。
■在使用托法替尼治疗后观察到患者的爆发和瘙痒的显著缓解。然而,剂量减少后复发。随后转换为高选择性JAK1抑制剂upadacitinib导致完全恢复，患者在六个月后达到无症状状态。
JAK抑制剂有望成为对传统疗法无反应的EPF患者的潜在治疗选择。
